The 55% reduction in relapse rate compared to Rebif® over the two years of the study (p<0.0001) is not as good as the 74% rate after 3 years from phase II trial*, where it was also found to reduce the risk of sustained accumulation of disability by 71% (P<0.001 for both). Safety, on the other hand was better.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.